Background: Rotavirus (RV) causes a highly contagious gastroenteritis especially in children under five years of age. Since 2006 two RV-vaccines are available in Europe (Rotarix(®) and RotaTeq(®)). To support informed decision-making within the German Standing Committee on Vaccination (STIKO) the cost-effectiveness of these two vaccines was evaluated for the German healthcare setting.
Methods: A Markov model was developed to evaluate the cost-effectiveness from the statutory health insurance (SHI) and from the societal perspective. RV-cases prevented, RV-associated hospitalizations avoided, and quality-adjusted life years (QALY) gained were considered as health outcomes. RV-incidences were calculated based on data from the national mandatory disease reporting system. RV-vaccine efficacy was determined as pooled estimates based on data from randomized controlled trials. Vaccine list prices and price catalogues were used for cost-assessment. Effects and costs were discounted with an annual discount rate of 3%.
Results: The base-case analysis (SHI-perspective) resulted in an incremental cost-effectiveness and cost-utility ratio for Rotarix(®) of € 184 per RV-case prevented, € 2457 per RV-associated hospitalization avoided, and € 116,973 per QALY gained. For RotaTeq(®), the results were € 234 per RV-case prevented, € 2622 per RV-associated hospitalization avoided, and € 142,732 per QALY gained. Variation of various parameters in sensitivity analyses showed effects on the ICERs without changing the overall trend of base-case results. When applying base-case results to the 2012 birthcohort in Germany with 80% vaccination coverage, an estimated 206,000-242,000 RV-cases and 18,000 RV-associated hospitalizations can be prevented in this birthcohort over five years for an incremental cost of 44.5-48.2 million €.
Conclusion: Our analyses demonstrate that routine RV-vaccination could prevent a substantial number of RV-cases and hospitalizations in the German healthcare system, but the saved treatment costs are counteracted by costs for vaccination. However, with vaccine prices reduced by ∼62-66%, RV-vaccination could even become a cost-saving preventive measure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2014.01.061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Health checks for autistic adults: study protocol for a cluster randomised controlled trial.
Trials
December 2024
Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
Background: Autistic people commonly have physical and mental health conditions. They also frequently experience barriers to accessing healthcare, contributing to problems identifying and treating health conditions. These factors may lead to increased and earlier morbidity and lower average life expectancy for autistic people.
View Article and Find Full Text PDFDigital supportive supervision (DiSS) of maternal health, child health and nutrition (MCHN) service delivery in Rajasthan, India: study protocol for impact evaluation and cost-effectiveness analysis.
BMJ Open
December 2024
Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background: A digital supportive supervision (DiSS) tool was developed and implemented in Rajasthan, India, to enhance the coverage and quality of maternal health, child health and nutrition (MCHN) services. This study aims to assess the impact and cost-effectiveness of DiSS compared to traditional paper-based supportive supervision.
Methods And Analysis: A quasi-experimental research design incorporating interrupted time series regression analysis will be employed to evaluate the impact of DiSS.
Robotic arm-assisted medial compartment knee arthroplasty is a cost-effective intervention at ten-year follow-up.
Bone Joint J
January 2025
Department of Trauma and Orthopaedics, Glasgow Royal Infirmary, Glasgow, UK.
Aims: The aim of this study was to perform an incremental cost-utility analysis and assess the impact of differential costs and case volume on the cost-effectiveness of robotic arm-assisted medial unicompartmental knee arthroplasty (rUKA) compared to manual (mUKA).
Methods: Ten-year follow-up of patients who were randomized to rUKA (n = 64) or mUKA (n = 65) was performed. Patients completed the EuroQol five-dimension health questionnaire preoperatively, at three months, and one, two, five, and ten years postoperatively, which was used to calculate quality-adjusted life years (QALY) gained and the incremental cost-effectiveness ratio (ICER).
Cost-Effectiveness Analysis of Vaccination Compliance Strategies Using a Novel Hybrid Model for Influenza Vaccination.
China CDC Wkly
December 2024
Department of Biostatistics, School of Public Health, National Vaccine Innovation Platform, Nanjing Medical University, Nanjing City, Jiangsu Province, China.
Introduction: The cost-effectiveness of vaccination strategies plays a crucial role in managing infectious diseases such as influenza within public health systems. This study evaluated the cost-effectiveness of vaccination compliance strategies by comparing an "adherence" strategy, which promoted continuous vaccination uptake, with a "volunteer" strategy through model-based simulations.
Methods: We developed a novel hybrid model that integrates continuous-time agent-based models (ABMs) with a Markov model to simulate vaccination behaviors and disease dynamics at the individual level.
Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis.
Vaccine
December 2024
School of Population Health, Faculty of Medicine and Health, UNSW Sydney, New South Wales, Australia.
Background: Respiratory syncytial virus (RSV) is a major cause of respiratory illness, with younger infants at greatest risk of hospitalisation. With the recent approval of a maternal RSV vaccine in Australia, it is timely to evaluate its potential costs and health benefits in Australia.
Methods: We applied an integrated dynamic and economic evaluation model to estimate specific outcomes of RSV disease and the cost-effectiveness of a year-round maternal RSV vaccination program in Australia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!